Acceso a medicamentos: experiencias con licencias obligatorias y uso gubernamental – el caso de la Hepatitis C
Por Dr. Carlos M. Correa y Dr. Germán Velásquez
El acceso a medicamentos está fuertemente condicionado por su precio y por los mecanismos de financiamiento que pueden aplicarse en cada país. […] Un factor determinante en la fijación del precio de los medicamentos es el grado de competencia existente en una particular clase terapéutica, la que a su vez es influenciada por la existencia o no de derechos de propiedad intelectual, como patentes de invención.
South Centre Statement at the Meeting of Ministers of Health of the Member States of the Non-Aligned Movement
The South Centre reiterates its commitment to support the Non-Aligned countries so that there is close and effective cooperation among developing countries to strengthen a global health agenda. WHO was created as an international public agency in the service of global health. Recovering and reinforcing this role should be the work of all.
The IP Negotiations Monitor summarizes the latest developments in multilateral and regional fora where intellectual property negotiations are taking place, and informs on upcoming meetings and events.
This update provides a snapshot of the activities of the Development, Innovation and Intellectual Property Programme during the month of February 2018.
Outcomes of the 142nd session of the WHO Executive Board
The 142nd session of the WHO Executive Board discussed several critical public health issues including a recommendation to the WHA to approve the General Program of Work (GPW), the adoption of important decisions relating to access to medicines and research and development and a draft resolution on the preparation of the UN High Level Meeting on Tuberculosis.
This update provides a snapshot of the activities of the Development, Innovation and Intellectual Property Programme during the month of December 2017.
Heading off Global Action on Access to Medicines in 2018
By Dr. Jorge Bermudez and Dr. Viroj Tangcharoensathien
At the dawn of 2018, political and health leaders must seize the growing momentum and opportunities to tackle the protracted challenges of access to medicines that undermine efforts to save lives and improve health as committed under the Agenda 2030 SDG by all UN member states. (more…)
This update provides a snapshot of the activities of the Development, Innovation and Intellectual Property Programme during the month of November 2017.
The International Debate on Generic Medicines of Biological Origin
The debate on generic medicines is not new. What makes it different today is that attacks levelled against biological products are couched in ever more “technical” and abstruse language that confuses even the World Health Organization (WHO).
